About

Board of Directors

charles-baum

Charles Baum, MD, PhD

Chairperson of the Board
 

Dr. Baum is President, CEO, and Board Member of Mirati Therapeutics, where he built a world-class precision oncology leadership team, taken the company public on Nasdaq, and focused the company on targeted development of receptor tyrosine kinase and histone deacetylase inhibitors in various cancers. Prior to joining Mirati in 2012, he was at Pfizer since 2003, serving in roles of increasing responsibility including as Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research and Development division; Vice President and Head of Oncology Development; and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. At Pfizer, he was responsible for the development of the oncology portfolio, including axitinib (Inlyta®), crizotinib (Xalkori®) and the approval of sunitinib (Sutent®) for the treatment of gastrointestinal stromal tumor and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) which was approved for the treatment of patients with advanced brain tumors.  Dr. Baum currently serves on the board of directors of Array BioPharma and Immunomedics. He received his M.D. and Ph.D. in immunology from Washington University School of Medicine in St. Louis and completed his post-graduate training at Stanford University. Dr. Baum has published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.

Close
benjamin-rovinski

Benjamin Rovinski, PhD

Managing Director, Lumira Ventures
 

With more than 30 years of investment, operational, managerial and research experience in the healthcare industry, Benjamin (Beni) Rovinski, Ph.D., has helped build life sciences companies at all stages of development. Beni held several senior management positions in the biotechnology sector, including 13 years at Sanofi Pasteur (formerly Aventis Pasteur), where he led global research and development programs in the areas of HIV/AIDS and therapeutic cancer vaccines, bringing several of them through to clinical stage. Beni joined Lumira Ventures in 2001 and his current and past board roles include Antios Therapeutics; Antiva Biosciences; Aurinia Pharmaceuticals (Nasdaq: AUPH); Bright Angel Therapeutics; Deka Biosciences; G1 Therapeutics (Nasdaq: GTHX); Health Hero Network (acquired by Bosch); Iterion Therapeutics; KAI Pharmaceuticals (acquired by Amgen); Morphotek (acquired by Eisai); Notch Therapeutics; and SGX Pharmaceuticals (Nasdaq: SGXP; acquired by Eli Lilly). Beni also serves on the Board of Directors of Life Sciences Ontario and Ontario Genomics, and he volunteers for various personal career mentoring programs targeting young adult entrepreneurs.  Beni is a member of the Government of Canada COVID-19 Vaccine Task Force. Beni is fluent in English, French, and Spanish. He has published several scientific articles and reviews and is the recipient of over 30 issued patents. He received a Ph.D. in biochemistry from McGill University in Montréal and did postdoctoral studies in molecular oncology and retrovirology at the Ontario Cancer Institute in Toronto.

Close
widya-mulyasasmita

Widya Mulyasasmita, PhD

Senior Principal, Healthcare at B Capital Group
 

Widya Mulyasasmita, PhD, is a Sr. Principal on the Healthcare team at B Capital Group, where she focuses on investments in Biotech, Bio IT, and Innovative Med Tech. She brings diverse investing and operating experiences at the intersection of the life sciences, engineering, and technology. She currently serves on the board of directors at OncoMyx Therapeutics and is a board observer at HotSpot Therapeutics. Widya joins B Capital from Red Tree Venture Capital, where she invested in and helped launch biotech and medical device companies. Prior to Red Tree, Widya was Acting Chief Business Officer at xCella Biosciences (acq. by Ligand Pharmaceuticals) and was the founding Chief Business Officer at InterVenn Biosciences. Widya was previously Director of New Ventures at Johnson & Johnson Innovation, sourcing and managing partnership deals across the pharmaceutical and medical device sectors on the US West Coast and Australia. She came to J&J from McKinsey & Company, where she was a management consultant. Prior to McKinsey, she worked at GE Ventures Healthcare and co-founded a medical device startup, where she served as Chief Scientist. Widya received her B.S. in Materials Science and Bioengineering from the University of California Berkeley where she was awarded the Bioengineering Departmental Citation, and her Ph.D. in Bioengineering from Stanford University where she was a Stanford Graduate Fellow and a Siebel Scholar.

Close
kanad

Kanad Das, PhD

Executive Director, BIVF
 

Kanad joined Boehringer Ingelheim from Merck (MSD) where he was Director, Business Development and Licensing in their West Coast Innovation Hub. He evaluated assets in Immuno-Oncology, Cardiovascular and Metabolic Diseases and Ophthalmology in the preclinical space up to human proof of concept. Kanad started his career at Genentech as a post-doctoral fellow. He then worked as a medicinal chemist at KAI Pharmaceuticals, where he was an inventor of Parsabiv, approved in 2017 for the treatment of Secondary Hyperparathyroidism. After KAI, Kanad worked at Stanford University’s SPARK program, an academic accelerator designed to take basic science discoveries and bring them to fundable assets. He received his PhD in Chemistry from the University of Massachusetts, Amherst and a B.Sc. in Chemistry from UC Berkeley. Head of Oncology Development; and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. At Pfizer, he was responsible for the development of the oncology portfolio, including axitinib (Inlyta®), crizotinib (Xalkori®) and the approval of sunitinib (Sutent®) for the treatment of gastrointestinal stromal tumor and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) which was approved for the treatment of patients with advanced brain tumors.  Dr. Baum currently serves on the board of directors of Array BioPharma and Immunomedics. He received his M.D. and Ph.D. in immunology from Washington University School of Medicine in St. Louis and completed his post-graduate training at Stanford University. Dr. Baum has published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.

Close
tim

Tim Xiao, CFA, FRM

Partner, Delos Capital
 

Tim Xiao, CFA, FRM, is a Partner and founding team member at Delos Capital since its inception in 2014. Tim has over 14 years of experience in investment banking and life sciences investment. Tim started his career as an investment banker at China International Capital and later joined the Investment Banking Division of Goldman Sachs, where he completed a series of industry-defining transactions with a total deal value of over US$4 billion. Tim serves as a Board member for Eccogene, Clover Biopharmaceuticals, OncoMyx Therapeutics, Curatia Medical, STRM.Bio, and Thermalin and as a Board Observer for Allecra Therapeutics and Intrinsic Therapeutics. Tim was previously a Board member for Luqa Pharmaceuticals (acquired by China Medical System HKEx: 867). Tim holds a Bachelor’s degree in International Business from Shanghai Jiao Tong University and is a CFA charter holder.

Close
Steve Potts

Steve Potts, PhD, MBA

Cofounder, CEO & Director
 

Steve Potts, PhD, MBA (Cofounder & CEO) leads OncoMyx. Steve has worked in the biopharma industry since 1999 and has had experience in a wide range of areas, including product development, sales, marketing, and general management. He has a proven track record of success, with his last three companies all with significant shareholder returns. He was Vice President of Medical Affairs at Ignyta, which was acquired by Roche for $1.7B, and he led the global operation of the testing of 30,000 patients in an oncology basket trial for entrectinib in 15 countries. The molecule was the first in industry to receive breakthrough designation equivalents in the USA, Europe, and Japan. Prior to Ignyta, he bootstrapped his first company as founding CEO, Flagship Biosciences, to 75 employees and an exit for his investors. He was General Manager Life Sciences at Aperio, which exited to Danaher for $180M. He also built the Bioinformatics Department for a Fortune 500 Company, Quest Diagnostics, which subsequently delivered $1B of annual revenue. He earned a BS in Physics from Wheaton College, Illinois and PhD in Biological Engineering and MBA from the University of California Davis.

Close